Overview

Gender

male

John Niederhuber joined Inova as executive vice president and CEO of Inova Translational Medicine Institute (ITMI) in September 2010. As founder and leader of ITMI, he directs a program that integrates technical innovation, informatics and sophisticated genomic analyses with the goal of managing disease risk and delivering excellence in individualized (personalized) healthcare, research and education. Within his first year at Inova, he initiated the ITMI Preterm Birth Study. This study involves the whole genome sequencing of over 1000 families (mother, father & baby) with over 350 families having a preterm delivery.

Niederhuber launched the Fairfax County Longitudinal Childhood Cohort study involving 5,000 families in summer 2012. There are more than 2,500 families already enrolled. As a result, ITMI manages over 8,000 whole genome sequences in its extensive information analysis system and specimen biobank.

These families are followed through birth and at six month intervals thereafter. ITMI has several other genomic studies in progress all involving whole genome sequencing of family trios. ITMI has grown to over 80 employees and has developed clinical services in molecular diagnosis and clinical consultation in a CLIA-certified laboratory and through its physician-led Division of Medical Genomics.